|
US6361796B1
(en)
*
|
1996-10-25 |
2002-03-26 |
Shire Laboratories, Inc. |
Soluble form osmotic dose delivery system
|
|
US20090297602A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Devane John G |
Modified Release Loxoprofen Compositions
|
|
US20080113025A1
(en)
*
|
1998-11-02 |
2008-05-15 |
Elan Pharma International Limited |
Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
|
|
US20050119237A1
(en)
*
|
1999-06-18 |
2005-06-02 |
Ramot University Authority For Applied Research & Industrial Development Ltd. |
Non-malignant disease treatment with Ras antagonists
|
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
|
BR0109602A
(pt)
|
2000-03-30 |
2004-06-29 |
Bristol Myers Squibb Co |
Glóbulos de liberação controlada contendo estavudina
|
|
US20020068078A1
(en)
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
|
US20040122090A1
(en)
*
|
2001-12-07 |
2004-06-24 |
Lipton Stuart A. |
Methods for treating neuropsychiatric disorders with nmda receptor antagonists
|
|
US6720000B2
(en)
*
|
2001-03-19 |
2004-04-13 |
Three Rivers Pharmaceutical, Llc |
Process for producing wet ribavirin pellets
|
|
DE10137102A1
(de)
*
|
2001-07-30 |
2003-02-27 |
Deutsches Krebsforsch |
Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
|
|
US20040001886A1
(en)
*
|
2001-10-17 |
2004-01-01 |
Dr. Reddy's Laboratories Limited |
Stabilized pharmaceutical formulations containing amlodipine maleate
|
|
US6602911B2
(en)
|
2001-11-05 |
2003-08-05 |
Cypress Bioscience, Inc. |
Methods of treating fibromyalgia
|
|
US6635675B2
(en)
|
2001-11-05 |
2003-10-21 |
Cypress Bioscience, Inc. |
Method of treating chronic fatigue syndrome
|
|
US20030175346A1
(en)
*
|
2002-02-01 |
2003-09-18 |
Anne Billotte |
Osmotic delivery system
|
|
US20040038303A1
(en)
*
|
2002-04-08 |
2004-02-26 |
Unger Gretchen M. |
Biologic modulations with nanoparticles
|
|
WO2003096968A2
(en)
*
|
2002-05-15 |
2003-11-27 |
Sun Pharmaceutical Industries Limited |
Oral osmotic controlled drug delivery system
|
|
US20040033257A1
(en)
*
|
2002-05-30 |
2004-02-19 |
Strides Inc. |
Pharmaceutical formulation in a drug delivery system and process for preparing the same
|
|
WO2004026261A2
(en)
*
|
2002-09-19 |
2004-04-01 |
Three Rivers Pharmaceuticals, Llc |
Composition containing ribavirin and use thereof
|
|
US7538094B2
(en)
|
2002-09-19 |
2009-05-26 |
Three Rivers Pharmacueticals, Llc |
Composition containing ribavirin and use thereof
|
|
US20070077301A1
(en)
*
|
2002-12-23 |
2007-04-05 |
Meyer Glenn A |
Venlafaxine osmotic device formulation
|
|
EP1594515A4
(en)
*
|
2003-02-03 |
2009-05-27 |
Supernus Pharmaceuticals Inc |
FORMULATION AND ADMINISTRATION OF A MEDICINAL PRODUCT USING METHYLATED CRYSTALLINE CYCLODEXTRINS
|
|
ES2622471T5
(es)
|
2003-05-22 |
2020-07-23 |
United Therapeutics Corp |
Compuestos y procedimientos para la administración de análogos de prostaciclina
|
|
DE602004000260T2
(de)
|
2003-07-22 |
2006-08-24 |
Arena Pharmaceuticals, Inc., San Diego |
Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
|
|
US7611728B2
(en)
*
|
2003-09-05 |
2009-11-03 |
Supernus Pharmaceuticals, Inc. |
Osmotic delivery of therapeutic compounds by solubility enhancement
|
|
EP1715843A1
(en)
*
|
2004-01-29 |
2006-11-02 |
Neuromolecular Inc. |
Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
|
|
US7776358B2
(en)
*
|
2004-07-22 |
2010-08-17 |
Synthon Ip Inc. |
Extended release venlafaxine besylate tablets
|
|
US7619007B2
(en)
*
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
|
EP2623099A1
(en)
|
2004-11-24 |
2013-08-07 |
Neuromolecular Pharmaceuticals, Inc |
Composition and method for treating neurological disease
|
|
US8574626B2
(en)
|
2004-12-03 |
2013-11-05 |
Osmotica Kereskedelmi és Szolgáltató KFT |
Osmotic device containing amantadine and an osmotic salt
|
|
AR053986A1
(es)
|
2004-12-03 |
2007-05-30 |
Osmotica Pharmaceutical Argent |
Dispositivo osmotico que contiene amantadina y una sal osmotica
|
|
US8252331B2
(en)
*
|
2004-12-03 |
2012-08-28 |
Osmotica Kereskedelmi és Szolgáltató, KFT |
Osmotic device containing amantadine and an osmotic salt
|
|
US8128952B2
(en)
*
|
2005-01-12 |
2012-03-06 |
Clemson University Research Foundation |
Ligand-mediated controlled drug delivery
|
|
BRPI0606932A2
(pt)
*
|
2005-01-26 |
2009-07-28 |
Elan Pharma Int Ltd |
formulação, forma de dosagem, e, uso de uma quantidade terapeuticamente efetiva de uma formulação
|
|
US20070298098A1
(en)
*
|
2005-02-16 |
2007-12-27 |
Elan Pharma International Limited |
Controlled Release Compositions Comprising Levetiracetam
|
|
WO2006088864A1
(en)
*
|
2005-02-16 |
2006-08-24 |
Elan Pharma International Limited |
Controlled release compositions comprising levetiracetam
|
|
EP1855651A4
(en)
*
|
2005-03-03 |
2011-06-15 |
Elan Pharma Int Ltd |
NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES
|
|
ES2564187T3
(es)
|
2005-04-05 |
2016-03-18 |
Yale University |
Agentes de modulación de glutamato en el tratamiento de trastornos mentales
|
|
ATE481096T1
(de)
|
2005-04-06 |
2010-10-15 |
Adamas Pharmaceuticals Inc |
Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
|
|
GB2442615A
(en)
*
|
2005-04-12 |
2008-04-09 |
Elan Pharma Int Ltd |
Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer
|
|
US7919583B2
(en)
*
|
2005-08-08 |
2011-04-05 |
Discovery Genomics, Inc. |
Integration-site directed vector systems
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
US20090099031A1
(en)
*
|
2005-09-27 |
2009-04-16 |
Stemmer Willem P |
Genetic package and uses thereof
|
|
US7846445B2
(en)
*
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
|
JP2009509535A
(ja)
*
|
2005-09-27 |
2009-03-12 |
アムニクス， インコーポレイテッド |
タンパク様薬剤およびその使用
|
|
US7994220B2
(en)
*
|
2005-09-28 |
2011-08-09 |
Cypress Bioscience, Inc. |
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
|
WO2007059372A2
(en)
*
|
2005-11-09 |
2007-05-24 |
St. Jude Children's Research Hospital |
Use of chloroquine to treat metabolic syndrome
|
|
ES2530526T3
(es)
|
2005-12-30 |
2015-03-03 |
Zensun Shanghai Science And Technology Ltd |
Liberación extendida de neurregulina para mejorar la función cardíaca
|
|
US8747897B2
(en)
|
2006-04-27 |
2014-06-10 |
Supernus Pharmaceuticals, Inc. |
Osmotic drug delivery system
|
|
US8124598B2
(en)
*
|
2006-09-14 |
2012-02-28 |
Sharon Sageman |
7-keto DHEA for psychiatric use
|
|
TWI415845B
(zh)
|
2006-10-03 |
2013-11-21 |
Arena Pharm Inc |
用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
|
|
JP5393677B2
(ja)
|
2007-08-15 |
2014-01-22 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
|
|
JP2010536341A
(ja)
*
|
2007-08-15 |
2010-12-02 |
アムニクス， インコーポレイテッド |
生物学的に活性なポリペプチドの特性を改変するための組成物および方法
|
|
US20100160274A1
(en)
*
|
2007-09-07 |
2010-06-24 |
Sharon Sageman |
7-KETO DHEA for Psychiatric Use
|
|
CN101903324B
(zh)
|
2007-12-17 |
2013-07-03 |
联合治疗公司 |
一种制备Remodulin中的活性成分曲前列素的改良方法
|
|
US20110021538A1
(en)
|
2008-04-02 |
2011-01-27 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US20090311335A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Scott Jenkins |
Combination of a triptan and an nsaid
|
|
MX2011001384A
(es)
|
2008-08-06 |
2011-09-27 |
Gosforth Ct Holdings Pty Ltd |
Composiciones y metodos para tratar trastornos psiquiatricos.
|
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
|
CA2741731A1
(en)
*
|
2008-10-28 |
2010-06-03 |
Arena Pharmaceuticals, Inc. |
Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
|
|
ES2610356T3
(es)
|
2009-02-03 |
2017-04-27 |
Amunix Operating Inc. |
Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
|
|
CA2757979A1
(en)
*
|
2009-04-09 |
2010-10-14 |
Alkermes Pharma Ireland Limited |
Controlled-release clozapine compositions
|
|
KR101813727B1
(ko)
|
2009-06-08 |
2018-01-02 |
아뮤닉스 오퍼레이팅 인코포레이티드 |
성장 호르몬 폴리펩타이드 및 이를 제조하고 사용하는 방법
|
|
WO2010144508A1
(en)
|
2009-06-08 |
2010-12-16 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
|
CA2771999A1
(en)
|
2009-08-24 |
2011-03-10 |
Amunix Operating Inc. |
Coagulation factor vii compositions and methods of making and using same
|
|
CA2994873A1
(en)
*
|
2009-12-02 |
2011-06-09 |
Adamas Pharma, Llc |
Amantadine compositions and methods of use
|
|
GB201111712D0
(en)
|
2011-07-08 |
2011-08-24 |
Gosforth Ct Holdings Pty Ltd |
Pharmaceutical compositions
|
|
JP6256882B2
(ja)
|
2012-02-15 |
2018-01-10 |
アムニクス オペレーティング インコーポレイテッド |
第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
|
|
EP2822577B1
(en)
|
2012-02-15 |
2019-02-06 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii proteins
|
|
KR20150040917A
(ko)
|
2012-07-09 |
2015-04-15 |
포스모 메드, 잉크 |
막 매개성 정삼투를 사용하는 장치
|
|
CN113842362A
(zh)
|
2012-11-14 |
2021-12-28 |
格雷斯公司 |
含有生物活性材料与无序无机氧化物的组合物
|
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
|
TW202003554A
(zh)
|
2013-08-14 |
2020-01-16 |
美商百歐維拉提夫治療公司 |
因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
|
|
WO2015073736A1
(en)
|
2013-11-13 |
2015-05-21 |
Arbor Pharmaceuticals, Llc |
Methods and compositions for treating adhd
|
|
CN111700877A
(zh)
|
2014-09-03 |
2020-09-25 |
吉倪塞思公司 |
治疗性纳米粒子和相关的组合物、方法和系统
|
|
US9593061B2
(en)
|
2014-10-20 |
2017-03-14 |
United Therapeutics Corporation |
Synthesis of intermediates for producing prostacyclin derivatives
|
|
US10022355B2
(en)
|
2015-06-12 |
2018-07-17 |
Axovant Sciences Gmbh |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
|
|
AU2016288643A1
(en)
|
2015-07-02 |
2018-02-22 |
University Of Louisville Research Foundation, Inc. |
Edible plant-derived microvesicle compositions for delivery of miRNA and methods for treatment of cancer
|
|
BR112018000728A2
(pt)
|
2015-07-15 |
2018-09-04 |
Axovant Sciences Gmbh |
resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
|
|
EA201890423A1
(ru)
|
2015-08-03 |
2018-07-31 |
Биовератив Терапьютикс Инк. |
Слитые белки фактора ix, способы их получения и применения
|
|
MX2019006444A
(es)
|
2016-12-02 |
2019-10-30 |
Bioverativ Therapeutics Inc |
Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
|
|
WO2018175340A1
(en)
|
2017-03-20 |
2018-09-27 |
Sienna Biopharmaceuticals, Inc. |
Reduced exposure conjugates modulating therapeutic targets
|
|
US20190247331A1
(en)
|
2018-02-15 |
2019-08-15 |
Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság |
Composition and method for treating neurological disease
|
|
US10213394B1
(en)
|
2018-02-15 |
2019-02-26 |
Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság |
Composition and method for treating neurological disease
|
|
US10213393B1
(en)
|
2018-02-15 |
2019-02-26 |
Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság |
Composition and method for treating neurological disease
|
|
PL3793588T3
(pl)
|
2018-05-18 |
2025-09-01 |
Bioverativ Therapeutics Inc. |
Sposoby leczenia hemofilii a
|
|
KR20230041711A
(ko)
|
2020-06-25 |
2023-03-24 |
아뮤닉스 파마슈티컬스, 인크. |
Her-2 표적화 이중특이적 조성물 및 이의 제조 및 사용 방법
|
|
IL326413A
(en)
|
2023-08-08 |
2026-04-01 |
United Therapeutics Corp |
Method for producing an oral pharmaceutical osmotic system and a pharmaceutical batch produced using the same method
|